Drugmaker Novartis’ Super Bowl ad explained that prostate cancer screening starts with a simple blood test, aiming to dispel ...
Reductions in hot flashes/day and in daily hot flash scores seen with 2.5mg and 5mg oxybutynin versus placebo.
PHILADELPHIA, PA — Medicus Pharma Ltd. (Nasdaq: MDCX) has received clearance from the U.S. Food and Drug Administration to ...
Medicus Pharma (NASDAQ:MDCX) announced that it has received “study may proceed” clearance from the US Food and Drug ...
The phase 2b study is an open-label trial that will enroll 40 men with advanced prostate cancer who are appropriate candidates for ADT. Participants will receive an initial loading dose of teverelix ...
Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a precision guided biotech/life sciences company focused on advancing the clinical development ...
In its final draft guidance published on 24 October 2025, NICE approved darolutamide for adults with metastatic ...
Detailed price information for Medicus Pharma Ltd (MDCX-Q) from The Globe and Mail including charting and trades.
Almost three-fourths of patients with biochemically recurrent prostate cancer remained metastasis free at 5 years following ...
A five-year retrospective study led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center and published in ...
These results suggest that oxybutynin may offer a practical and effective option for managing ADT-associated hot flashes in ...
New research in the February 2026 issue of JNCCN-Journal of the National Comprehensive Cancer Network found that incorporating information from prostate-specific membrane antigen (PSMA) PET/CT scans ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results